U.S. Markets close in 4 hrs 46 mins

Roche Holding AG (RHHVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
384.31+2.14 (+0.56%)
As of 10:35AM EDT. Market open.
Sign in to post a message.
  • F
    From Mexico With Love
    60 by years end
  • b
    Did 3 million shares really get traded today first thing in the morning on the NYSE? Maybe Yahoo has a typo?
  • M
    When is Gild acquisition?
  • s
  • V
    Strong run of diagnostics continues in this company.
  • S
    Sailor Al H
    What moved the stock today?
  • B
    Initiate acquisition mode #srpt
  • B
    FDA APPROVED - Roche test kits
  • H
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
  • B
    You should buy ACIU (AC IMMUNE) if you want Alzheimer drug exposure, with among the best risk/rewards I have ever seen. ACIU has the broadest portfolio of development stage Azlheimer's drugs with top partners such as Biogen, Eli Lilly, Roche and AbbVie. ACIU has the potential to earn $15 bil in revenues from royalties and payments The market cap of the company is only $400 mil, with $316 mil of net cash, resulting of an enterprise value of only $87 mil. If even one of ACIU's drugs go into commercial production, the stock could go up 10x or more, with limited near-term downside due to the company's strong cash position. ACIU has several drugs in its development pipeline in both stage 1 and stage 2 development, so investors have many shots at goal. There is a huge catalyst coming up on Nov 7th when the company will host a conference on the progress of their drug candidates. Investors have not started paying attention yet, but I think that will happen shortly. I have attached a recent positive recommendation on the stock from Value Investors, which is among the most reputable investors club. https://www.valueinvestorsclub.com/idea/AC_IMMUNE_SA/9888338509
  • c
    Ark Invest has begun purchasing RHHBY in their ARKG fund. I believe it's due to Roche's heavy investment in individualized cancer immunotherapy. Roche plans to deliver individualized blood testing on individuals with cancer to determine their cancer's genetic profile. The cancers genetic profile will then be used to individualize cancer therapies to the patients. Also, according to Morningstar, Roche is a wide moat stock that is very undervalued (five stars). Long!!!!!
  • A
    Roche (OTCQX:RHHBY) unit, Genentech announces that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the FDA, in combination with Tecentriq (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).
    Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
  • T
    To clarify further on the two analyzers from Roche, the newest one can analyze over 4000 cases in 24 hours and have the results within four hours. There are quite a large number of analyzers in the United States and in the rest of the world. Now a patient can get their results within a few hours, not days or weeks which is important to the growth  statistics to determine what’s happening in our country in any locale.
  • A
    This company would have to cure cancer for it to move up significantly. Good news almost every week and ARK buying thousands of shares and it goes down or barely moves up.
  • S
    Roche approaching another new high... Slowly but surely creating wealth for shareholders. Best in class biotech and diagnostics play IMO.
  • D
    We hear so much about the test kits and that is fine. But, the great news that we don't hear much about is Roche's drug Actemra which blocks the function of interleukin-6 causing inflammation in the lungs for those infected with the Corona virus. It was used with success to keep people off ventilators in China who did well. All 21 people in their trial did well. It was also used with success in Italy. The results were impressive so says Regeneron who has a similar drug called Kevzara. They have started a trial with their drug which could be ready in abundance by summer. So, Regeneron stock is soaring . Roche stock should be soaring as well.
  • b
    Okay, now that it's approved the US Government should put it to good use. The Red Cross is clearly in need of blood during this pandemic and the Roche test requires a blood draw. The government should provide these tests to the Red Cross so that they can encourage Americans to come in, give blood and get a free anti body test for their efforts. I'm sure they are many people who don't want to go into a standard lab right now. I suspect that there are just as many who don't want to give blood. But if one can give blood in a Covid free environment and get antibody test in the process then it sounds like a win win for everyone.
  • w
    My RHBBY div was credited to my brokerage AC on Monday.
    Unlike in the past, the foreign withholding was MUCH greater; the net (including 0.02/sh ADR fee) amount I received was .67849/share
    1.0746 - 0.37611 (taxes) - 0.02 = .67849

    In the previous three years I've had a position, 15% of the gross dividend was withheld for foreign taxes, but this year 35% was withheld.

    Comments from those more schooled in this?
  • A
    Nothing seems to move this stock. News of an FDA approval and it goes down.